Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 1,703

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study

Open access
Crump, Michael, Neelapu, Sattva S., Farooq, Umar, Van Den Neste, Eric, Kuruvilla, John, Westin, Jason, Link, Brian K., Hay, Annette, Cerhan, James R., Zhu, Liting, Boussetta, Sami, Feng, Lei, Maurer, Matthew J., Navale, Lynn, Wiezorek, Jeff, Go, William Y., Gisselbrecht, Christian·2017·Blood
DOI 10.1182/blood-2017-03-769620
Open this paper in CoChat — free account

Abstract

Key Points: SCHOLAR-1 is the first patient-level analysis of outcomes of refractory DLBCL from 2 large randomized trials and 2 academic databases. SCHOLAR-1 demonstrated poor outcomes in patients with refractory DLBCL, supporting a need for more effective therapies for these patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2017-03-769620

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 32

  1. Teras, 2016 US lymphoid malignancy statistics by World Health Organization subtypes [published online ahead of print 12 September 2016], CA Cancer J Clin
  2. Tilly, 2012, Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 23, vii78, 10.1093/annonc/mds273 · DOI · Paper page
  3. Sant, 2014, Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study, Lancet Oncol, 15, 931, 10.1016/S1470-2045(14)70282-7 · DOI · Paper page
  4. International Non-Hodgkin’s Lymphoma Prognostic Factors Project, 1993, A predictive model for aggressive non-Hodgkin’s lymphoma, N Engl J Med, 329, 987, 10.1056/NEJM199309303291402 · DOI · Paper page
  5. Sehn, 2007, The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP, Blood, 109, 1857, 10.1182/blood-2006-08-038257 · DOI · Paper page
  6. Crump, 2014, Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12, J Clin Oncol, 32, 3490, 10.1200/JCO.2013.53.9593 · DOI · Paper page
  7. Gisselbrecht, 2010, Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era, J Clin Oncol, 28, 4184, 10.1200/JCO.2010.28.1618 · DOI · Paper page
  8. Van Den Neste, 2016, Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study, Bone Marrow Transplant, 51, 51, 10.1038/bmt.2015.213 · DOI · Paper page
  9. Hamadani, 2014, Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation, Biol Blood Marrow Transplant, 20, 1729, 10.1016/j.bbmt.2014.06.036 · DOI
  10. Gisselbrecht, 2012, Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma, J Clin Oncol, 30, 4462, 10.1200/JCO.2012.41.9416 · DOI · Paper page
  11. Nagle, 2013, Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era, Am J Hematol, 88, 890, 10.1002/ajh.23524 · DOI
  12. Kochenderfer, 2013, Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors, Nat Rev Clin Oncol, 10, 267, 10.1038/nrclinonc.2013.46 · DOI · Paper page
  13. Hitz, 2010, Outcome of patients with chemotherapy refractory and early progressive diffuse large B Cell lymphoma after R-CHOP treatment [abstract], Blood, 116, 10.1182/blood.V116.21.1751.1751 · doi:10.1182/blood.v116.21.1751.1751
  14. Seshadri, 2008, Salvage therapy for relapsed/refractory diffuse large B cell lymphoma, Biol Blood Marrow Transplant, 14, 259, 10.1016/j.bbmt.2007.11.013 · doi:10.1016/j.bbmt.2007.11.013
  15. Telio, 2012, Salvage chemotherapy and autologous stem cell transplant in primary refractory diffuse large B-cell lymphoma: outcomes and prognostic factors, Leuk Lymphoma, 53, 836, 10.3109/10428194.2011.643404 · DOI
  16. Ardeshna, 2005, Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens, Br J Haematol, 130, 363, 10.1111/j.1365-2141.2005.05603.x · DOI
  17. Josting, 2000, Treatment of primary progressive Hodgkin’s and aggressive non-Hodgkin’s lymphoma: is there a chance for cure?, J Clin Oncol, 18, 332, 10.1200/JCO.2000.18.2.332 · DOI
  18. Matasar, 2013, Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma, Blood, 122, 499, 10.1182/blood-2012-12-472027 · DOI
  19. Moskowitz, 1999, Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin’s lymphoma, J Clin Oncol, 17, 3776, 10.1200/JCO.1999.17.12.3776 · DOI · Paper page
  20. Philip, 1995, Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma, N Engl J Med, 333, 1540, 10.1056/NEJM199512073332305 · DOI · Paper page
  21. Van Den Neste, 2017, Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study, Bone Marrow Transplant, 52, 216, 10.1038/bmt.2016.213 · DOI
  22. Seshadri, 2008, Utility of subsequent conventional dose chemotherapy in relapsed/refractory transplant-eligible patients with diffuse large B-cell lymphoma failing platinum-based salvage chemotherapy, Hematology, 13, 261, 10.1179/102453308X343527 · DOI
  23. Thompson, 2014, Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma, J Clin Oncol, 32, 3506, 10.1200/JCO.2014.55.7561 · DOI · Paper page
  24. Maurer, 2014, Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy, J Clin Oncol, 32, 1066, 10.1200/JCO.2013.51.5866 · DOI · Paper page
  25. Cuccuini, 2012, MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation, Blood, 119, 4619, 10.1182/blood-2012-01-406033 · doi:10.1182/blood-2012-01-406033
  26. Casulo, 2015, Transformed follicular non-Hodgkin lymphoma, Blood, 125, 40, 10.1182/blood-2014-04-516815 · DOI · Paper page
  27. Harris, 2013, Shades of gray between large B-cell lymphomas and Hodgkin lymphomas: differential diagnosis and biological implications, Mod Pathol, 26, S57, 10.1038/modpathol.2012.182 · DOI
  28. Petković, 2015, Current trends in the treatment of primary mediastinal large B-cell lymphoma - an overview, Contemp Oncol (Pozn), 19, 428
  29. Cheson, 1999, Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas, J Clin Oncol, 17, 1244, 10.1200/JCO.1999.17.4.1244 · DOI · Paper page
  30. van Kampen, 2011, Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin’s lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry, J Clin Oncol, 29, 1342, 10.1200/JCO.2010.30.2596 · DOI · Paper page
  31. Sehn, 2015, Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity, Blood, 125, 22, 10.1182/blood-2014-05-577189 · DOI · Paper page
  32. Costa, 2017, Diffuse large B-cell lymphoma with primary treatment failure: ultrahigh risk features and benchmarking for experimental therapies, Am J Hematol, 92, 161, 10.1002/ajh.24615 · doi:10.1002/ajh.24615

Cited by

See all 1,703

Metadata

Authors
Crump, M., Neelapu, S. S., Farooq, U., Van Den Neste, E., Kuruvilla, J., Westin, J., Link, B. K., Hay, A., Cerhan, J. R., Zhu, L., Boussetta, S., Feng, L., Maurer, M. J., Navale, L., Wiezorek, J., Go, W. Y., & Gisselbrecht, C.
Venue
Blood
Publisher
American Society of Hematology
Published
2017-10-19
Volume
130
Issue
16
Pages
1800-1808
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
DOI
10.1182/blood-2017-03-769620
OpenAlex
W2744261860
Cited by
1,703
References
2
FWCI
74.17
Type
journal article
Language
en
Update notices
erratum (2018-02-01)
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. https://app.cochat.ai/papers/10.1182/blood-2017-03-769620
The paper
Crump, M., Neelapu, S. S., Farooq, U., Van Den Neste, E., Kuruvilla, J., Westin, J., Link, B. K., Hay, A., Cerhan, J. R., Zhu, L., Boussetta, S., Feng, L., Maurer, M. J., Navale, L., Wiezorek, J., Go, W. Y., & Gisselbrecht, C. (2017). Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. https://doi.org/10.1182/blood-2017-03-769620

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.